5 Critical Biotech Drug Dates and Events for December
At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 277Regenerative Medicine Company on Track for IPO This Week
The week after the Thanksgiving holiday stacks up to be another quiet one on the IPO front.
Mixed Readings For Biotech Short Interest
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them.…
Amgen Surprise, Discontinues Stomach Cancer Drug Study
ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue was made based on…
Big News for Ebola Stocks
Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks.
5 Health Care Stocks That Need to Play Serious Catch Up
24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to catch up to peers.
4 More Biotech Stocks to Buy, With Up to 200% Upside
As the Stifel health care conference continues, the firm posts four more stocks that it rates Buy that have incredible upside potential.
4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential
A new report from the biotech team at Stifel focuses on catalysts from companies that are presenting at the firm's annual health care conference.
Is Orexigen Really Worth Over 50% More?
Merrill Lynch released an analyst report for Orexigen Therapeutics that sees more than 50% upside for the company.
The Devastating Cost of Alzheimer’s Care
Providing care for a parent or loved one with Alzheimer's disease or other dementia costs $20,000 or more for 42% of Americans.
Is This the Sunesis Resurrection?
On Monday, Sunesis made an announcement that it would be making a presentation regarding its drug candidates vosaroxin and cytarabine.
Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out
Botox maker Allergan has entered a definitive agreement to be acquired by Actavis, despite higher offer from Valeant Pharmaceuticals.
Juno Therapeutics Files for IPO
Juno Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
What Licensing Imetelstat Will Mean for Geron
Geron hasannounced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat.
ReWalk Earnings Shine Spotlight on Robotics
ReWalk Robotics reported quarterly earnings Thursday morning for the first time since the company's initial public offering in mid-September.